183 related articles for article (PubMed ID: 26763180)
21. Fabry disease: a review of current management strategies.
Mehta A; Beck M; Eyskens F; Feliciani C; Kantola I; Ramaswami U; Rolfs A; Rivera A; Waldek S; Germain DP
QJM; 2010 Sep; 103(9):641-59. PubMed ID: 20660166
[TBL] [Abstract][Full Text] [Related]
22. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
[TBL] [Abstract][Full Text] [Related]
23. [Management of Fabry disease].
Constantin T; Székely A; Ponyi A; Gulácsy V; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Medvecz M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Rákóczi E; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G
Orv Hetil; 2010 Aug; 151(31):1243-51. PubMed ID: 20656661
[TBL] [Abstract][Full Text] [Related]
24. Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey.
Barba-Romero MÁ; Pintos-Morell G
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27886142
[TBL] [Abstract][Full Text] [Related]
25. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
26. Enzyme replacement therapy and renal function in 201 patients with Fabry disease.
Schwarting A; Dehout F; Feriozzi S; Beck M; Mehta A; Sunder-Plassmann G;
Clin Nephrol; 2006 Aug; 66(2):77-84. PubMed ID: 16939062
[TBL] [Abstract][Full Text] [Related]
27. Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis.
Lee CL; Lin SP; Niu DM; Lin HY
Int J Med Sci; 2022; 19(1):126-131. PubMed ID: 34975306
[No Abstract] [Full Text] [Related]
28. Higher apoptotic state in Fabry disease peripheral blood mononuclear cells.: effect of globotriaosylceramide.
De Francesco PN; Mucci JM; Ceci R; Fossati CA; Rozenfeld PA
Mol Genet Metab; 2011 Nov; 104(3):319-24. PubMed ID: 21724436
[TBL] [Abstract][Full Text] [Related]
29. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine.
Rombach SM; van den Bogaard B; de Groot E; Groener JE; Poorthuis BJ; Linthorst GE; van den Born BJ; Hollak CE; Aerts JM
Hypertension; 2012 Oct; 60(4):998-1005. PubMed ID: 22868390
[TBL] [Abstract][Full Text] [Related]
30. Fabry disease - Vascular manifestations.
Karetova D; Bultas J; Dostalova G; Palecek T; Kovarnik T; Golan L; Linhart A
Vasa; 2010 May; 39(2):123-31. PubMed ID: 20464667
[TBL] [Abstract][Full Text] [Related]
31. Metronomic breathing shows altered parasympathetic baroreflex function in untreated Fabry patients and baroreflex improvement after enzyme replacement therapy.
Hilz MJ; Koehn J; Kolodny EH; Brys M; Moeller S; Stemper B
J Hypertens; 2011 Dec; 29(12):2387-94. PubMed ID: 21970939
[TBL] [Abstract][Full Text] [Related]
32. Fabry disease: overall effects of agalsidase alfa treatment.
Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
[TBL] [Abstract][Full Text] [Related]
33. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
Kampmann C; Linhart A; Devereux RB; Schiffmann R
Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
[TBL] [Abstract][Full Text] [Related]
34. Cardiac challenges in patients with Fabry disease.
Weidemann F; Linhart A; Monserrat L; Strotmann J
Int J Cardiol; 2010 May; 141(1):3-10. PubMed ID: 19720409
[TBL] [Abstract][Full Text] [Related]
35. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
[TBL] [Abstract][Full Text] [Related]
36. Unravelling the mechanism of action of enzyme replacement therapy in Fabry disease.
Ko Y; Lee C; Moon MH; Hong GR; Cheon CK; Lee JS
J Hum Genet; 2016 Feb; 61(2):143-9. PubMed ID: 26490183
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic goals in the treatment of Fabry disease.
Mehta A; West ML; Pintos-Morell G; Reisin R; Nicholls K; Figuera LE; Parini R; Carvalho LR; Kampmann C; Pastores GM; Lidove O
Genet Med; 2010 Nov; 12(11):713-20. PubMed ID: 20975569
[TBL] [Abstract][Full Text] [Related]
38. Residual Volume and Total Lung Capacity to Assess Reversibility in Obstructive Lung Disease.
McCartney CT; Weis MN; Ruppel GL; Nayak RP
Respir Care; 2016 Nov; 61(11):1505-1512. PubMed ID: 27555617
[TBL] [Abstract][Full Text] [Related]
39. Correlations Between Serum Cholesterol and Vascular Lesions in Fabry Disease Patients.
Katsuta H; Tsuboi K; Yamamoto H; Goto H
Circ J; 2018 Nov; 82(12):3058-3063. PubMed ID: 30282881
[TBL] [Abstract][Full Text] [Related]
40. Contribution of inflammatory pathways to Fabry disease pathogenesis.
Rozenfeld P; Feriozzi S
Mol Genet Metab; 2017 Nov; 122(3):19-27. PubMed ID: 28947349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]